Premium
RD Lawrence Lecture 2008 Targeting GLP‐1 release as a potential strategy for the therapy of Type 2 diabetes
Author(s) -
Gribble F. M.
Publication year - 2008
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2008.02514.x
Subject(s) - medicine , postprandial , glucagon like peptide 1 , type 2 diabetes , appetite , hormone , endocrinology , endocrine system , insulin , endogeny , enteroendocrine cell , gastrointestinal hormone , diabetes mellitus , peptide yy , pharmacology , peptide hormone , neuropeptide , receptor , neuropeptide y receptor
Abstract Glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) are gastrointestinal hormones that play an important role in stimulating postprandial insulin release from pancreatic β‐cells. Agents that either mimic GLP‐1 or prevent its degradation are now available for the treatment of Type 2 diabetes, and strategies to enhance endogenous GLP‐1 release are under assessment. As intestinal peptides have a range of actions, including appetite regulation and coordination of fat metabolism, harnessing the enteric endocrine system is a promising new field for drug development.